These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37527414)

  • 1. Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
    Bhardwaj M; Gour A; Ahmed A; Dhiman S; Manhas D; Khajuria P; Wazir P; Mukherjee D; Nandi U
    Mol Pharm; 2023 Sep; 20(9):4597-4610. PubMed ID: 37527414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
    Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
    Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O
    Trials; 2021 Aug; 22(1):561. PubMed ID: 34425873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir for the treatment of COVID-19.
    Santani BG; LeBlanc BW; Thakare RP
    Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine.
    Venkatanarayana P; Kolli D; Seelama NV; Ramakrishna DS
    Nucleosides Nucleotides Nucleic Acids; 2023; 42(6):427-435. PubMed ID: 36472346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
    Cox RM; Wolf JD; Plemper RK
    Nat Microbiol; 2021 Jan; 6(1):11-18. PubMed ID: 33273742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of molnupiravir for COVID-19 patients.
    Fatima M; Azeem S; Saeed J; Shahid A; Cheema HA;
    Eur J Intern Med; 2022 Aug; 102():118-121. PubMed ID: 35649740
    [No Abstract]   [Full Text] [Related]  

  • 12. Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
    Miller SR; McGrath ME; Zorn KM; Ekins S; Wright SH; Cherrington NJ
    Mol Pharmacol; 2021 Dec; 100(6):548-557. PubMed ID: 34503974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N
    Bluemling GR; Mao S; Natchus MG; Painter W; Mulangu S; Lockwood M; De La Rosa A; Brasel T; Comer JE; Freiberg AN; Kolykhalov AA; Painter GR
    Antiviral Res; 2023 Jan; 209():105453. PubMed ID: 36379378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression.
    Franco EJ; Drusano GL; Hanrahan KC; Warfield KL; Brown AN
    Viruses; 2023 May; 15(5):. PubMed ID: 37243261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.
    Ahlqvist GP; McGeough CP; Senanayake C; Armstrong JD; Yadaw A; Roy S; Ahmad S; Snead DR; Jamison TF
    ACS Omega; 2021 Apr; 6(15):10396-10402. PubMed ID: 34056192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir.
    Al-Taie A; Denkdemir FR; Sharief Z; Buyuk AS; Şardaş S
    OMICS; 2022 Jun; 26(6):324-328. PubMed ID: 35580151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
    Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
    Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
    Painter WP; Holman W; Bush JA; Almazedi F; Malik H; Eraut NCJE; Morin MJ; Szewczyk LJ; Painter GR
    Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33649113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.